C07D 515/00
Heterocyclic compounds containing in the condensed system at least one hetero ring
Official title: Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
C07D515/00 (Heterocyclic compounds containing in the condensed system at least one hetero ring) appears on 197 US grants and 284 published applications in this corpus.
Search patents in C07D- Granted patents
- 197
- Published applications
- 284
- Assignees
- 174
- Inventors
- 1,095
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 4 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 5 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 1 |
| 2002 | 3 | 2 |
| 2003 | 4 | 3 |
| 2004 | 2 | 8 |
| 2005 | 4 | 1 |
| 2006 | 2 | 9 |
| 2007 | 5 | 5 |
| 2008 | 4 | 7 |
| 2009 | 2 | 10 |
| 2010 | 7 | 5 |
| 2011 | 7 | 7 |
| 2012 | 5 | 5 |
| 2013 | 4 | 12 |
| 2014 | 11 | 8 |
| 2015 | 6 | 7 |
| 2016 | 8 | 11 |
| 2017 | 13 | 11 |
| 2018 | 5 | 12 |
| 2019 | 12 | 10 |
| 2020 | 4 | 10 |
| 2021 | 13 | 21 |
| 2022 | 14 | 18 |
| 2023 | 5 | 37 |
| 2024 | 13 | 28 |
| 2025 | 11 | 21 |
| 2026 | 8 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Orexin receptor agonists and uses thereof29 Sep 2026US 12,747,252 B2Jazz Pharmaceuticals Ireland Limited
- Macrocyclic compounds, compositions, and methods of using thereof9 Jun 2026US 12,649,750 B2Genzyme Corporation
- Macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them2 Jun 2026US 12,643,912 B2Les Laboratoires Servier
- Macrocyclic compounds, compositions, and methods of using thereof12 May 2026US 12,624,051 B2Genzyme Corporation
- Modulators of cystic fibrosis transmembrane conductance regulator28 Apr 2026US 12,612,416 B2Vertex Pharmaceuticals Incorporated
- Novel compound or salt thereof, catalyst, method of preparing novel compound or salt thereof and method of preparing mannich product8 Oct 2026US 2026/0308178 A1Okinawa Institute of Science and Technology School Corporation
- Ras inhibitors1 Oct 2026US 2026/0297112 A1Revolution Medicines, Inc.
- Macrocyclic compounds as usp1 inhibitors24 Sep 2026US 2026/0285876 A1Guangdong Newopp Biopharmaceuticals Co., Ltd.
- Novel compounds and uses thereof13 Aug 2026US 2026/0234163 A1Acelink Therapeutics, Inc.
- Ecteinascidin derivative antibody drug conjugates6 Aug 2026US 2026/0224720 A1Adcytherix SAS
Most cited
By later US patents
- Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith44US 5,256,663 AThe Board of Trustees of the University of Illinois · 1993
- Fluorescent complex and lighting system using the same39US 7,902,741 B2Kabushiki Kaisha Toshiba · 2011
- Ecteinascidins 736 and 72237US 5,149,804 AThe Board of Trustees of the University of Illinois · 1992
- Hybrid cyclic libraries and screens thereof36US 9,250,237 B2The Johns Hopkins University · 2016
- Nucleophile substituted ecteinascidins and N-oxide ecteinascidins33US 5,985,876 A1999